Recent advances in targeted therapy and immunotherapy have once again raised the hope
that a cure might be within reach for many cancer types. Yet, most late-stage cancers are …

Nanocarriers have been widely employed in preclinical studies and clinical trials for the
delivery of anticancer drugs. The most important causes of failure in clinical translation of …

Bacteria are emerging as living drugs to treat a broad range of disease indications.
However, the inherent advantages of these replicating and immunostimulatory therapies …

Medicine relies on the use of pharmacologically active agents (drugs) to manage and treat
disease. However, drugs are not inherently effective; the benefit of a drug is directly related …

Precise targeting and high therapeutic efficiency are the major requisites of personalized
cancer treatment. However, some unique features of the tumor microenvironment (TME) …

Synthetic carriers such as polymer and lipid particles often struggle to meet clinical
expectations. Natural particulates—that range from pathogens to mammalian cells—are …

Recent advancements in cancer biology, microbiology, and bioengineering have spurred
the development of engineered live biotherapeutics for targeted cancer therapy. In …

There is growing interest in the role of microorganisms in human health and disease, with
evidence showing that new types of biotherapy using engineered bacterial therapeutics …

Bacteria can sense their environment, distinguish between cell types, and deliver proteins to
eukaryotic cells. Here, we engineer the interaction between bacteria and cancer cells to …

It was already clinically apparent 150 years ago that bacterial therapy could alleviate
diseases. Recently, a burgeoning number of researchers have been using bacterial …